These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 19166333

  • 1. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA, Obach RS.
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [Abstract] [Full Text] [Related]

  • 2. Metabolites and safety: What are the concerns, and how should we address them?
    Smith DA, Obach RS.
    Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
    [Abstract] [Full Text] [Related]

  • 3. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC.
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [Abstract] [Full Text] [Related]

  • 4. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA, Obach RS.
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [Abstract] [Full Text] [Related]

  • 5. Metabolites in safety testing.
    Robison TW, Jacobs A.
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [Abstract] [Full Text] [Related]

  • 6. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T, Lin JH, Baillie TA.
    Toxicol Appl Pharmacol; 2006 Dec 01; 217(2):143-52. PubMed ID: 17055014
    [Abstract] [Full Text] [Related]

  • 7. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, Scatina J.
    Chem Res Toxicol; 2009 Feb 01; 22(2):311-22. PubMed ID: 19067650
    [Abstract] [Full Text] [Related]

  • 8. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH.
    Chem Res Toxicol; 2009 Jul 01; 22(7):1217-20. PubMed ID: 19563206
    [Abstract] [Full Text] [Related]

  • 9. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP.
    Chem Res Toxicol; 2009 Feb 01; 22(2):237-8. PubMed ID: 19216576
    [No Abstract] [Full Text] [Related]

  • 10. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L, Gocke E, Lavé T, Pfister T.
    Toxicol Lett; 2009 Nov 12; 190(3):317-29. PubMed ID: 19443141
    [Abstract] [Full Text] [Related]

  • 11. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD.
    Chem Res Toxicol; 2011 Sep 19; 24(9):1345-410. PubMed ID: 21702456
    [Abstract] [Full Text] [Related]

  • 12. Saturable metabolism and its relationship to toxicity.
    Andersen ME.
    Crit Rev Toxicol; 1981 May 19; 9(2):105-50. PubMed ID: 7026174
    [Abstract] [Full Text] [Related]

  • 13. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW, Frederick CB, Sistare FD, DeGeorge JJ.
    Chem Res Toxicol; 2009 Feb 19; 22(2):257-62. PubMed ID: 19170595
    [Abstract] [Full Text] [Related]

  • 14. Strategy for genotoxicity testing--metabolic considerations.
    Ku WW, Bigger A, Brambilla G, Glatt H, Gocke E, Guzzie PJ, Hakura A, Honma M, Martus HJ, Obach RS, Roberts S, Strategy Expert Group, IWGT.
    Mutat Res; 2007 Feb 03; 627(1):59-77. PubMed ID: 17141553
    [Abstract] [Full Text] [Related]

  • 15. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M, Zhang D, Zhang H, Shyu WC.
    Biopharm Drug Dispos; 2009 May 03; 30(4):163-84. PubMed ID: 19544287
    [Abstract] [Full Text] [Related]

  • 16. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA.
    Chem Res Toxicol; 2009 Feb 03; 22(2):263-6. PubMed ID: 19216579
    [Abstract] [Full Text] [Related]

  • 17. Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity.
    Smith DA, Obach RS, Williams DP, Park BK.
    Chem Biol Interact; 2009 Apr 15; 179(1):60-7. PubMed ID: 18930037
    [Abstract] [Full Text] [Related]

  • 18. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, Wright P.
    Chem Res Toxicol; 2009 Oct 15; 22(10):1653-62. PubMed ID: 19715349
    [Abstract] [Full Text] [Related]

  • 19. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA, Dorato MA.
    Regul Toxicol Pharmacol; 2009 Aug 15; 54(3):301-7. PubMed ID: 19477212
    [Abstract] [Full Text] [Related]

  • 20. Effect of overloading pathways on toxicity.
    Wolf FJ.
    J Environ Pathol Toxicol; 1980 Aug 15; 3(5-6):113-34. PubMed ID: 7441076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.